Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and LITT in Recurrent Glioblastoma
NCT03341806Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jun 2018
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avelumab in glioblastoma (GBM), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Dose Limiting Toxicity level at 4 weeks and Objective response rate at 6 months. Started Jun 2018; status: completed.
02
Drugs
avelumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03341806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341806.